ArticleJournal of cancer research and clinical oncology2023

Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting.

Shanshan Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.